Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTI-2040 + Docetaxel in Advanced Solid Tumors and NSCLC
NCT00074022Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2003
- Primary completion
- Nov 2007
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GTI-2040 in non-small cell lung cancer (NSCLC), prostate cancer (PCa) and solid tumor, sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicities at 21 days and Objective Tumor Response at 42 days. Started Oct 2003; status: completed.
02
Drugs
GTI-2040
03
Conditions
non-small cell lung cancer (NSCLC)prostate cancer (PCa)solid tumor
Beyond the preview
Go deeper on NCT00074022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074022.